Tehran University of Medical Sciences Journal of Pharmaceutical Care 2322-4630 1 3 2015 10 10 90 94 EN Arezoo Ahmadi Anesthesiology and Intensive Care Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Mojtaba Mojtahedzadeh Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Farzaneh Javadi Clinical Pharmacy Department, Faculty of Pharmacy, Islamic Azad University of Medical Sciences, Tehran, Iran. Mohammad Abdollahi Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University of Medical Sciences, Tehran, Iran. Atabak Najafi Anesthesiology and Intensive Care Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Sarah Mousavi Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 2015 10 10 2015 10 10 Background: An increased oxidative stress in patients under treatment with high concentrations of oxygen (hyperoxia) is considered to be one of the major mechanisms of lung injury. Between different mediators, transition metal ions especially iron, by generation of very reactive free radicals play an important role in oxidative stress process. Disruption of normal iron hemostasis has been reported in hyperoxic conditions. So we hypothesized that chelation of iron can reduce hyperoxia- induced lung injury. Methods: Mechanically ventilated patients, who received oxygen with FiO > 0.5 for at least 3 days, underwent bronchoscopy at baseline and 72 hours thereafter. Data from external control cases were collected prospectively to provide a comparative reference group.Iron and Iron-related proteins were measured in lavage fluid and plasma. Results: In 24 patients and in comparison with the results of previous study, Iron concentration decreased significantly in lavage fluid (P<0.001). Reduction of ferritin was not significant in lavage fluid (P: 0.7).Transferrin decreased significantly in plasma (P: 0.01). Acute Physiology And Chronic Health Evaluation (APACHE) II (P: 0.006) score decreased significantly after 7 days of follow-up. Conclusion: Deferasirox did not change Iron and Iron-related protein in hyperoxic condition and it just only could be considered along with other supportive measures for better toleration of oxygen therapy. https://jpc.tums.ac.ir/index.php/jpc/article/view/21 https://jpc.tums.ac.ir/index.php/jpc/article/download/21/21